Tonix Pharmaceuticals Holding (TNXP) Depreciation & Amortization (CF) (2017 - 2026)

Tonix Pharmaceuticals Holding has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $619000.0 in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 28.16% year-over-year to $619000.0 in Q2 2026; TTM through Jun 2026 was $2.1 million, a 7.11% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, down 43.73% from the prior year.
• Depreciation & Amortization (CF) was $619000.0 for Q2 2026 at Tonix Pharmaceuticals Holding, up from $555000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.3 million in Q4 2023, with the low at $63000.0 in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $669055.6, with a median of $532500.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 2996.3% in 2022, then slumped 60.67% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $836000.0 in 2022, then jumped by 50.84% to $1.3 million in 2023, then tumbled by 60.67% to $496000.0 in 2024, then declined by 1.61% to $488000.0 in 2025, then increased by 26.84% to $619000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $619000.0 (Q2 2026), $555000.0 (Q1 2026), and $488000.0 (Q4 2025), per Business Quant data.